医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

First Singapore Patient Receives Orthocell’s Cartilage Cell Therapy Ortho-ACI™

2015年11月18日 AM08:57
このエントリーをはてなブックマークに追加


 

PERTH, Australia

Regenerative medicine company Orthocell Limited is pleased to announce its regenerative cell therapy treatment, Ortho-ACITM, has been applied to its first patient in Singapore.

Singapore is the latest international market Orthocell has expanded Ortho-ACITM into, following its successful entry to Hong Kong earlier this year where the therapy was used on patients with articular cartilage damage within the knee joint.

Ortho-ACITM involves taking cartilage cells from a patient via a biopsy, expanding the cell volume in a Therapeutic Goods Authority (TGA)-licensed laboratory (Lic # MI-19052008-LI-002420-11) and then implanting these cells surgically back into the area of cartilage damage to regenerate the lost tissue.

Managing Director Paul Anderson said, “The availability of this technology puts Australia and the region at the very forefront of the provision of a sophisticated, high quality and cost effective regenerative treatment to help people with painful and difficult to treat cartilage injuries that often lead to osteoarthritis if left untreated.

“Singapore is the latest country where Ortho-ACI™ has been used as we continue to expand our reach into the region from our state-of-the-art production facility in Australia.”

Leading Singaporean orthopaedic surgeon Dr Derrick Oh completed the Ortho-ACITM implantation at Gleneagles Hospital, Singapore. Ortho-ACI™ is a cellular therapy for the regeneration of articular cartilage of the joints, offering a high quality, cost effective, customized approach and is currently being used by orthopaedic key opinion leaders in Australia, New Zealand, Hong Kong and Singapore.

The global regenerative medicine market has been forecast to reach $US67.6 billion in 2020, from $US16.4 billion in 2014, with the Asia-Pacific region expected to be the fastest growing region1.

1. http://www.prnewswire.co.uk/news-releases/regenerative-medicine-market-is-expected-to-reach-676-billion-global-by-2020-265200791.html

About Orthocell Limited

Orthocell is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151117007098/en/

CONTACT

General enquiries
Orthocell Limited
Paul Anderson, (08)
9360 2888
Managing Director
paulanderson@orthocell.com.au
or
Investor
relations

Buchan Consulting
Ben Walsh, + 61 468 422 865
bwalsh@buchanwe.com.au
or
Media
enquiries

Buchan Consulting
Gavin Lower, (03) 8866 1215 /
0414 796 726
glower@buchanwe.com.au

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果